Oral suspension versus tablet sildenafil for erectile dysfunction: a prospective multicenter comparative study on patient satisfaction
Abstract
New formulations of sildenafil, such as oral suspension, may improve onset of action and patient acceptability. This prospective, non-randomized, multicenter observational study compared sildenafil oral suspension (SiSUS) and sildenafil tablets (SiTAB) in treatment-naïve men with erectile dysfunction (ED). Patients from four urology centers in Madrid selected either SiSUS (Bandol®, AspargoLabs Inc., NY, USA) or SiTAB after standardized counseling and received on-demand treatment for eight weeks. Primary outcome was patient satisfaction assessed by the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire; secondary outcomes included changes in the International Index of Erectile Function-Erectile Function (IIEF-15) scores, latency to erection, and adverse events. A total of 133 patients completed the study (SiSUS: 64; SiTAB: 69). Both groups showed significant improvement in IIEF-15 scores (mean ΔIIEF-15: 17.41 ± 12.46 vs. 17.33 ± 15.02; p = 0.977). Median EDITS score was similar for both groups (77.27 vs. 61.36; p = 0.1312), with significantly greater satisfaction for SiSUS in those men ≤65 (77.27 vs 52.27, p = 0.0486). Median and interquartile ranges (IQR) times for latency to erection were shorter in the SiSUS group: 30 (30-45) vs. 60 (50-60) min; p < 0.0001). Adverse events were comparable (26.6 vs. 21.7%; p = 0.6547), with headache being the most frequent for both groups (12.5, vs 10.14%, p = 0.3244). Limitations include the observational,…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.